An Open-label, Single Dose, Parallel Group Study to Assess the Effects of Smoking Status, Age and Body Size on the Pharmacokinetics, Safety, and Tolerability of Tasimelteon in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2012
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders; Insomnia; Major depressive disorder
- Focus Pharmacokinetics
- 19 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Nov 2011 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.